Drugs / Novavax recombinant protein vaccine
Novavax recombinant protein vaccine
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT07287137 Comparator | Nov 2025 → Sep 2027 expected | COVID-19, influenza | Henry M. Jackson Foundation for the Advancement of Military Medicine | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Novavax recombinant protein vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07287137 ↗ |
| Modality | Protein / enzyme biologic | “Novavax recombinant protein vaccine” NCT07287137 ↗ |